138 related articles for article (PubMed ID: 8683247)
1. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.
Saven A; Lee T; Kosty M; Piro L
J Clin Oncol; 1996 Jul; 14(7):2139-44. PubMed ID: 8683247
[TBL] [Abstract][Full Text] [Related]
2. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
[TBL] [Abstract][Full Text] [Related]
3. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Van Den Neste E; Louviaux I; Michaux JL; Delannoy A; Michaux L; Sonet A; Bosly A; Doyen C; Mineur P; André M; Straetmans N; Coche E; Venet C; Duprez T; Ferrant A
Leukemia; 2000 Jun; 14(6):1136-42. PubMed ID: 10865980
[TBL] [Abstract][Full Text] [Related]
5. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma.
Robak T; Gora-Tybor J; Urbańska-Ryś H; Krykowski E
Leuk Lymphoma; 1999 Jan; 32(3-4):359-63. PubMed ID: 10037034
[TBL] [Abstract][Full Text] [Related]
6. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
8. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.
Hoffman M; Tallman MS; Hakimian D; Janson D; Hogan D; Variakogis D; Kuzel T; Gordon LI; Rai K
J Clin Oncol; 1994 Apr; 12(4):788-92. PubMed ID: 7908690
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.
McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Pate O; Romaguera JE; Rodriguez MA; Redman JR; Keating M
J Clin Oncol; 1994 Mar; 12(3):575-9. PubMed ID: 8120556
[TBL] [Abstract][Full Text] [Related]
10. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
[TBL] [Abstract][Full Text] [Related]
11. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
[TBL] [Abstract][Full Text] [Related]
12. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Robak T; Boński JZ; Kasznicki M; Góra-Tybor J; Hellmann A; Konopka L; Dmoszyńska A; Dwilewicz-Trojaczek J; Wołowiec D;
Eur J Haematol; 2002 Jul; 69(1):27-36. PubMed ID: 12270059
[TBL] [Abstract][Full Text] [Related]
13. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
McLaughlin P; Hagemeister FB; Romaguera JE; Sarris AH; Pate O; Younes A; Swan F; Keating M; Cabanillas F
J Clin Oncol; 1996 Apr; 14(4):1262-8. PubMed ID: 8648382
[TBL] [Abstract][Full Text] [Related]
15. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
16. New prospects in the treatment of indolent lymphomas with purine analogues.
Cheson BD
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S27-36. PubMed ID: 9672772
[TBL] [Abstract][Full Text] [Related]
17. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.
Armitage JO; Tobinai K; Hoelzer D; Rummel MJ
Int J Hematol; 2004 May; 79(4):311-21. PubMed ID: 15218957
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.
Tefferi A; Witzig TE; Reid JM; Li CY; Ames MM
J Clin Oncol; 1994 Mar; 12(3):569-74. PubMed ID: 8120555
[TBL] [Abstract][Full Text] [Related]
19. Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
Robak T; Szmigielska-Kapłon A; Błoński JZ; Kasznicki M; Chojnowski K
Chemotherapy; 2005 Aug; 51(5):247-51. PubMed ID: 16088121
[TBL] [Abstract][Full Text] [Related]
20. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
